The clinical lab of specialty cancer diagnostics company Precipio Inc. was able to detect oncogene isoform co-expression in a leukemia patient using a specialized panel.
Precipio leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a patient with a history of Chronic Myeloid Leukemia (CML) and p210 isoform expression, which allowed the lab to uncover an additional oncogene isoform expression: p190.
While many labs only monitor previously detected mutations for analysis of Minimal Residual Disease Status (MRD) for CML patients, utilization of the HemeScreen BCR-ABL1 Panel enabled Precipio’s clinical lab to detect a co-expression of both p190 and p210 isoforms in this patient, leading to more informed care decisions for the treating physician.
Changes in isoform expression may happen over time during the course of treatment. The HemeScreen BCR-ABL1 panel simultaneously detects four oncogene isoforms including p190, p203, p210, and p230 to provide a comprehensive, easy-to-use assay for its clinical lab.
“This case is a perfect example of why we developed the HemeScreen platform with a panel-based approach to ensure we are providing doctors a more comprehensive picture of their patients’ molecular status,” says Ilan Danieli CEO. “We, and our customers, continue to see the benefits of using the HemeScreen BCR-ABL1 panel both in lab operations efficiencies and results such as these that enable doctors to make more informed care decisions.”
Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise, and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics, and treatment, Precipio offers a high standard of diagnostic accuracy to enable the highest level of patient care.